Last 5 Years Refereed Scholarly Publications, 2020-2024

Research Articles

• Moustafa DA, Shafei L, Sulaiman R, Yassin MA, Abushanab D, Algarabli Y, Al-Badriyeh D. Efficacy and safety of daratumumab for the treatment of refractory/relapsed multiple myeloma. A systematic review of meta-analyses. J Oncol Pharm Pract. 2024. doi: 10.1177/10781552241290452. Epub ahead of print.

• Abushanab D, Mohammed S, Abdel-Latif R, Al-Muftah W, Ismail SI, Al Hail M, Al-Marridi W, Abdallah O, Al-Khuzaei N, Al-Thani A, Al-Badriyeh D. Cost-effectiveness analysis of genotype-guided optimization of major depression treatment in Qatar. J Pharm Policy Pract. 2024;17(1):2410197.

• Abushanab D, Al-Badriyeh D, Marquina C, Morton JI, Lloyd M, Zomer E, Talic S, Liew D, Ademi Z. The Reduction of the Productivity Burden of Cardiovascular Disease by Improving the Risk Factor Control Among Australians with Type 2 Diabetes: A 10-Year Dynamic Analysis. Eur J Prev Cardiol. 2024. doi: 10.1093/eurjpc/zwae292. Epub ahead of print.

• Kang W, Peng K, Yan VKC, Al-Badriyeh D, Lee SF, Yiu HHE, Wei Y, Li STH, Ye X, El Helali A, Lam KO, Lee VHF, Wong ICK, Chan EW. Direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer-associated venous thrombosis: a cost-effectiveness analysis. J Pharm Policy Pract 2024;17(1):2375269.

• Abushanab D, Chbib S, Kaddoura R, Al Hail M, Abdul Rouf PV, El Kassem W, Shah J, Ravindran Nair RK, Al-Badriyeh D. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes. J Med Econ 2024; 27(1):404-417.

• Abushanab D, Al-Marridi W, Al Hail M, Abdul Rouf PV, ElKassem W, Thomas B, Alsoub H, Ademi Z, Hanssens Y, Enany RE, Al-Badriyeh D. The cost associated with the development of the antimicrobial stewardship program in the adult general medicine setting in Qatar. J Pharm Policy Pract 2024; 17(1):2326382.

• Abushanab D, Al-Badriyeh D, Marquina C, Liew D, Zidan M, Al-Kuwari M, Abdulmajeed J, Ademi Z. Correction to ‘Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model’. Diabetes, Obesity and Metabolism 2024; 26(1), 148-159.

• Abdel-Latif R, Badji R, Mohammed S, Al-Muftah W, Mbarek H, Darwish D, Assaf D, Al-Badriyeh D, Elewa H, Afifi N, Masoodi NA, Omar AS, Al Suwaidi J, Bujassoum S, Al Hail M, Ismail SI, Althani A. QPGx-CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies. Clin Transl Sci 2024; 17(6):e13800.

• Al-Hersh E, Abushanab D, AbouNahia F, Rainkie D, Al Hail M, Abdulrouf PV, El-Kassem W, Al-Badriyeh D. A cost-effectiveness analysis for high versus standard (low) dose caffeine for the treatment of apnea in neonatal intensive care unit. J Pharm Policy Pract 2024;17(1):2345218.

• Shafei L, Bashir S, Chan EW, Abushanab D, Hamad A, Al-Badriyeh D. Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis. Curr Probl Cancer. 2024;50:101076.

• Kaddoura R, Madurasinghe V, Chapra A, Abushanab D, Al-Badriyeh D, Patel A. Beta-blocker therapy in heart failure with preserved ejection fraction (B-HFpEF): A systematic review and meta-analysis. Current Problems in Cardiology 2024; 49(3): 102376.

• Yakti O, Al-Badriyeh D, Rijims M, Abdelaal M, Alsoukhni O, Al Hail M, Abdulrouf PV, El-Kassem W, Abounahia F, Kaddoura R, Abushanab D. Clinical pharmacists’ interventions for preventing adverse events in critically ill neonates in Qatar: an economic impact analysis. Journal of Pharmaceutical Policy and Practice 2024; 17(1): 170-190.

• Adel AM, Abushanab D, Al-Badriyeh D, Hamad A, Alshurafa A, Yassin MA. Cost-effectiveness of l-glutamine versus crizanlizumab for adults with sickle cell disease: model focused on reducing pain episode costs from Qatar’s healthcare perspective. SAGE Open Med 2024; 12:20503121231224551.

• Al-Shaibi S, Abushanab D, Abounahia F, Awaisu A, Al-Badriyeh D. Letter to Editor on Fawad et al. Comment on “Cost-effectiveness analysis of ibuprofen versus indomethacin or paracetamol for the treatment of patent ductus arteriosus in preterm neonates” by Al-Shaibi et al. Current Problems in Cardiology 2024; 49(1 Pt C): 102157.

• Abushanab D, Al-Badriyeh D, Marquina C, Liew D, Zidan M, Al-Kuwari M, Abdulmajeed J, Ademi Z. Societal Health and Economic Burden of Cardiovascular Diseases in the Type 2 Diabetes Population in Qatar. A 10-Year Forecasting Model. Diabetes, Obesity and Metabolism 2024; 26(1): 148-159.

• Al Dali S, Al-Badriyeh D, Gulied A, Hamad A, Hail MA, Rouf PVA, El-Kassem W, Abushanab D. Characteristics of the clinical pharmacist interventions at the National Center for Cancer Care and Research Hospital in Qatar. Journal of Oncology Pharmacy Practice 2024; 30(5): 792-801.

• Naseralallah L, Al-Badriyeh D, Atchan M, Abdul Rouf P, Al Hail M, El-Kassem W, Abushanab D. Characteristics of the clinical pharmacist interventions at the main general tertiary hospital in Qatar. Qatar Medical Journal 2023; 2023(4): 28.

• Mohammedain SA, Badran S, Elzouki AY, Salim H, Chalaby A, Siddiqui M, Hussein YY, Rahim HA, Thalib L, Alam MF, Al-Badriyeh D, Al-Maadeed S, Doi SA. Validation of a risk prediction model for COVID-19: the PERIL prospective cohort study. Future Virology 2023; 18(5): 991–999.

• Al-Shaibi S, Abushanab D, Abounahia F, Awaisu A, Al-Badriyeh D. Cost-effectiveness analysis of ibuprofen versus indomethacin or paracetamol for the treatment of patent ductus arteriosus in preterm neonates. Current Problems in Cardiology 2023; 48(9): 101751.

• Abushanab D, Marquina C, Morton JI, Al-Badriyeh D, Lloyd M, Magliano DJ, Liew D, Ademi Z. Projecting the health and economic burden of cardiovascular disease among people with type 2 diabetes, 2022-2031. Pharmacoeconomics 2023; 41(6): 719-732.

• Al-Badriyeh D, Kaddoura R, AlMaraghi F, Homosy A, Hail MA, El-Kassem W, Abdul Rouf P, Fadul A, Mahfouz A, Alyafei SA, Abushanab D. Impact of clinical pharmacist interventions on economic outcomes in a cardiology setting in Qatar. Current Problems in Cardiology 2023; 48(9): 101838.

• Abushanab D, Atchan M, Elajez R, Elshafei M, Abdelbari A, Al Hail M, Abdulrouf PV, El-Kassem W, Ademi Z, Fadul A, Abdalla E, Diab MI, Al-Badriyeh D. Economic impact of clinical pharmacist interventions in a general tertiary hospital in Qatar. PLoS One 2023; 18(6): e0286419.

• Eljaam M, Al-Naimi H, Haddad M, Abushanab D, Al-Badriyeh D. Comparative efficacy and safety among high-intensity statins. A systematic review and meta-analysis. Journal of Comparative Effectiveness Research 2023; 12(3): e220163.

• Abushanab D, Gulied A, Hamad A, Abutineh M, Abdul Rouf P, Al Hail M, ElKassem W, ElHajj M, Al-Badriyeh D. Cost savings and cost avoidance with the inpatient clinical pharmacist interventions in a tertiary cancer care hospital. Journal of Oncology Pharmacy Practice 2023; 29(8):1935-1943.

• Kaddoura R, Al-Badriyeh D, Abushanab D, Al-Hijji M. Percutaneous mitral-valve intervention for secondary mitral regurgitation: Data from real-life. Current Problems in Cardiology 2023 17; 48(10): 101889.

• Abushanab D, Al-Badriyeh D, Marquina C, Bailey C, Jaam M, Liew D, Ademi Z. A systematic review of cost-effectiveness of non-statin lipid-lowering drugs for primary and secondary prevention of cardiovascular disease in patients with type 2 diabetes. Current Problems in Cardiology 2023; 48(8): 101211.

• Hamad A, Elazzazy S, Bujassoum S, Rasul K, Gaziev J, Cherif H, Al-Boloshi Z, Hanssens Y, Saleh A, Rasheed HA, Al-Badriyeh D, Babiker A, Hmaidan AA, Al-Hail M. Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP). BMC Health Serv Res 2023; 23(1): 15.

• Al-Badriyeh D. A National health strategy in the state of Qatar, mandatory health insurance scheme, 2023. ISPOR Global Network 2023; May 18.

• Eljilany I, Elewa H, Al-Badriyeh D. Cost-benefit analysis of genotype-guided interruption days in warfarin pre-procedural management. Current Problems in Cardiology 2023; 48(6): 101128.

• Abushanab D, Eldebs M, Basha A, Naseralallah L, Kazkaz H, Moursi A, Al-Bazoon F, Wafi O, Badran S, Doi S, Al-Maadeed S, Alam M, Al-Badriyeh D. The economic impact of optimizing a COVID-19 management protocol in pre-existing cardiovascular disease patients. Current Problems in Cardiology 2023; 48(8): 101177.

• Abushanab D, Hssain A, Al-Badriyeh D.Cost-effectiveness analysis of out-of-hospital versus in-hospital extracorporeal cardiopulmonary resuscitation for out-hospital refractory cardiac arrest. Current Problems in Cardiology 2022; 47(12): 101387.

• Kaddoura R, Al-Badriyeh D, Abushanab D, Al-Hijji M. Transcatheter mitral-valve repair for functional mitral regurgitation data from the real-life in comparison with landmark randomized trials. European Heart Journal 2022; 42 (S2): ehac544.2121

• Mukhalalati B, Elshami S, Adlan O, Elshazly M, Awaisu A, Stewart D, Al-Badriyeh D, Alali F. Perceptions and experiences of undergraduate pharmacy students and alumni towards research after exposure to undergraduate research courses. Frontiers in Medicine, Section Healthcare Professions Education 2022; 9: 988908.

• Kaddoura R, Abushanab D, Al-Arabi AR, Al-Badriyeh D. Cost-effectiveness analysis of sacubitril/valsartan for reducing the use of implantable cardioverter-defibrillator (ICD) and the risk of death in ICD-eligible heart failure patients with reduced ejection fraction. Current Problems in Cardiology 2022; 47(12): 101385.

• Pathadka S, Yan VKC, Neoh CF, Al-Badriyeh D, Kong DCM, Slavin MA, Cowling BJ, Hung IFN, Wong ICK, Chan EW. Authors’ reply to denning: comment on: “Global consumption trend of antifungal agents in humans from 2008 to 2018: data from 65 middle- and high-income countries”. Drugs 2022; 82: 1755–1756.

• Abushanab D, Nasr Z, Al-Badriyeh D. Efficacy and safety of colistin versus tigecycline for multi-drug-resistant and extensively drug-resistant gram-negative pathogens – A meta-analysis. Antibiotics 2022; 11(11): 1630.

• Pathadka S, Yan VKC, Neoh CF, Al-Badriyeh D, Kong DCM, Slavin MA, Cowling BJ, Hung IFN, Wong ICK, Chan EW. Global consumption trend of antifungal agents in humans from 2008 to 2018: data from 65 middle- and high-income countries. Drugs 2022; 82(11): 1193-1205.

• Osman A, Al-Badriyeh D, Hussain F, Riaz S, Elewa H, Mraiche F. The design and implementation of an undergraduate health professional degree elective course on scientific writing, peer assessment and critical appraisal. Currents in Pharmacy Teaching and Learning 2022; 14(6): 765-772.

• Kaddoura R, Mohamed MI, Al-Badriyeh D, Omar A, Al-Kindi F, Arabi A. Intracoronary pharmacolo-gical therapy versus aspiration thrombectomy in patients presenting with ST-segment elevation myocardial infarction: A systematic review and meta-analysis. PLosOne 2022; 17(5): e0263270.

• Abushanab D, Al-Badriyeh D, Liew D, Ademi Z. First-line treatment with empagliflozin and metformin combination versus standard care for patients with type 2 diabetes mellitus and cardiovascular disease in Qatar. A cost-effectiveness analysis. Current Problems in Cardiology 2022; 47(6): 100852.

• Abushanab D, Liew D, Marquina C, Al-Badriyeh D, Ademi Z. Cost-effectiveness of empagliflozin and metformin combination versus standard care as first-line therapy in patients with type 2 diabetes mellitus. Endocrine Practice 2022; 28(1): 16-24.

• Eljilany I, Elarref M, Shallik N, Elzouki AN, Bader L, El-Bardissy A, Abdelsamad O, Al-Badriyeh D, Cavallari LH, Elewa H. Genetic and non-genetic factors impact on INR normalization in preprocedural warfarin management. Pharmacogenomics and Personalized Medicine 2021; 14: 1069-1080.

• Almukdad S, Elewa H, Al-Badriyeh D. Short- and long-term cost-effectiveness of cyp2c19 genotype-guided therapy, universal clopidogrel, and universal ticagrelor in post-percutaneous coronary intervention patients in Qatar. International Journal of Cardiology 2021; 331: 27-34.

• Eljilany I, Elarref M, Shallik N, Elzouki AN, Mohammed A, Shoman B, Ibrahim S, Carr C, Al-Badriyeh D, Cavallari LH, Elewa H. Corrigendum to “periprocedural anticoagulation management of patients receiving warfarin in Qatar: a prospective cohort study”. Current Problems in Cardiology 2021; 46(12): 100899.

• Kaddoura R, Mohamed MI, Al-Badriyeh D, Omar A, Al-Kindi F, Arabi A. Intracoronary pharmacolo-gical therapy versus aspiration thrombectomy in patients presenting with ST-segment elevation myocardial infarction (IPAT-STEMI): A systematic review and meta-analysis. European Heart Journal 2021; 42(S1): 2112.

• Eljilany I, Elewa H, Abdelsamad O, Abdelgelil M, Mahfouz A, Anany RA, Yafei SA, Al-Badriyeh D. Bridging vs non-bridging with warfarin peri-procedural management: cost and cost-effectiveness analyses. Current Problems in Cardiology 2021; 46(11): 100839.

• Al-Shaibi S, Abushanab D, Alhersh E, Kaddoura R, Abdul Rouf P, Al-Badriyeh D. Use of ibuprofen for the closure of patent ductus arteriosus in preterm infants: a systematic review of meta-analyses. Journal of Comparative Effectiveness Research 2021; 10(7): 549-568.

• Eljilany I, Elarref M, Shallik N, Elzouki AN, Mohammed A, Shoman B, Ibrahim S, Carr C, Al-Badriyeh D, Cavallari LH, Elewa H. Periprocedural anticoagulation management of patients receiving warfarin in Qatar: a prospective cohort study. Current Problems in Cardiology 2021; 46(6): 100816.

• Abushanab D,Abdul Rouf P,Al Hail M,Kamal R,Viswanathan B,Parappil H, Elkassem W,Al-Shaibi S,Al-Badriyeh D. Cost-effectiveness of oral versus intravenous ibuprofen therapy in preterm infants with patent ductus arteriosus in the neonatal intensive care setting: A cohort-based study. Clinical Therapeutics 2021; 43(2): 336-348.

• Abushanab D,Al-Badriyeh D.Efficacy and safety of ibuprofen plus paracetamol fixed-dose combination for acute postoperative pain in adults: a meta-analysis. CNS Drugs 2021; 35(1): 105-120

• AbuShanab D, Alsoukhni O, Fouad AbouNahia, Al-Badriyeh D. Clinical and economic evaluation of the impact of midazolam on morphine therapy for pain relief in critically ill ventilated infants with respiratory distress syndrome. Pediatric Drugs 2021; 32(2): 143-157

• Eljilany I, El-Bardissy A, Nemir A, Elzouki AN, El Madhoun I, Al-Badriyeh D, Elewa H. Assessment of the attitude, awareness and practice of periprocedural warfarin management among health care professional in Qatar. A cross sectional survey. Journal of Thrombosis and Thrombolysis 2020;50(4): 957–968.

• AlMukdad S, Elewa, H, Al-Badriyeh D. Economic evaluation of CYP2C19 genotype-guided antiplatelet therapy compared to the universal use of antiplatelets in patients with acute coronary syndrome. A systematic review. Journal of Cardiovascular Pharmacology and Therapeutics 2020;25(3): 201-211.

• Alhersh E, Abushanab D, Al-Shaibi S, Al-Badriyeh D. Caffeine for the treatment of apnea in the neonatal intensive care unit: a systematic overview of meta-analyses. Pediatric Drugs 2020; 22(4): 399-408.

• Al‐Sulaiti F, Nader A, El‐Mekaty E, Elewa H, Al-Badriyeh D, El-Zubair A, Saad M, Awaisu A. Vancomycin therapeutic drug monitoring service quality indices and clinical effectiveness outcomes: A retrospective cohort and clinical audit. American College of Clinical Pharmacy 2020;3: 778–785.

• Abdelaal MA, Abushanab D, Al-Badriyeh D. Surfactant therapy for meconium aspiration syndrome in neonates: a systematic overview of systematic reviews and recent clinical trials. Journal of Comparative Effectiveness Research 2020; 9(8): 527-536.

• Al-Qudah R, Al-Badriyeh D, Al-Ali F, Al-Tawalbeh S, Basheti I. Cost-benefit analysis of clinical pharmacist intervention in preventing adverse drug events in the general chronic diseases outpatients. Journal of Evaluation in Clinical Practice 2020;26(1): 115-124.

Research Proceedings

• Zidan A., Hamad A.I., Al-Malki H.A., Alkadi M.M., Elesnawi M.A., Ibrahim R.A., Al-Badriyeh D., Hadi M.A., Awaisu A. 1 Effectiveness of a Multidisciplinary Team Delivered Deprescribing Intervention for Patients with CKD in Qatar: A Preliminary Analysis. Journal of the American Society of Nephrology 2024 35 (594-)

• Kaddoura R., Al-Badriyeh D., Abushanab D., Al-Hijji M. Temporal trends in characteristics and outcomes in patients undergoing percutaneous mitral valve repair for secondary mitral regurgitation. European Heart Journal 2023 44 Supplement 2

• Abushanab D, Al-Badriyeh D, Rijims M, Abdul Rouf P, Al Hail M, Elkassem W, Abdelaal M. Economic impact of clinical pharmacist interventions in the neonatal intensive care unit in Qatar. Value in Health 2023; 26: suppl 6 (S132-)

• Abushanab D, Al-Badriyeh D, Almarridi W, Al Hail M, Abdul Rouf P, Elkassem W, Thomas B, Al Soub H, Hanssens Y, El Enany R.  The Economic impact of antimicrobial stewardship program in the adults’ general medicine setting in Qatar. Value in Health 2023; 26: suppl 6 (S103-)

• Abushanab D, Al-Badriyeh D, Abdul Rouf P, Al Hail M, Elkassem W, Thomas B, Elshafey N, Eljilany I. Impact of Clinical Pharmacist Interventions on Economic Outcomes in Women’s Wellness and Research Center in Qatar. Value in Health 2023; 26: suppl 6 (S78-)

• Aldali S, Al-Badriyeh D, Gulied A, Hamad A, Al Hail M, Abdul Rouf P, Elkassem W, Abushanab D. Characteristics of the Clinical Pharmacist Interventions at a Tertiary Cancer Care Hospital in Qatar. Value in Health 2023; 26: suppl 6 (S154-)

• Abushanab D, Nasr Z, Al-Badriyeh D. Efficacy and safety of colistin versus tigecycline for multidrug-resistant and extensively drug-resistant gram-negative infections: a meta-analysis. JACCP, Journal of the American College of Clinical Pharmacy 2022; 5: 12 (1481-1482)

• Abushanab D, Atchan M, Elajez R, Nabil M, Abdelbari A, Al Hail M, Abdul Rouf P, Elkassem W, Diab M, Al-Badriyeh D. Economic impact of pharmacist participation in clinical rounds at a general tertiary hospital in Qatar. Value in Health 2022; 25: suppl 7 (s377-)

• Abushanab D, Naseralallah L, Al-Badriyeh D, Atchan M, Elajez R, Nabil M, Abdelbari A, Elkassem W, Abdul Rouf P, Al Hail M. Characteristics of interventions reported by clinical pharmacists at a general hospital. A cross-sectional study. Value in Health 2022; 25: suppl 7 (s378-s379)

• Kaddoura R, Abushanab D, Arabi A.R, Al-Badriyeh D. Cost-effectiveness analysis of sacubitril/valsartan in implantable cardioverter-defibrillator eligible patients. Value in Health 2022; 25: suppl 7 (s419-)

• Abushanab D, Mohammed R, Kaddoura R, Almaraghi F, Farhat A, Mahfouz A, Abdul Rouf P, Elkassem W, Al Hail M, Al-Saadi Al Yafei S, Al-Badriyeh D. Description of clinical pharmacists reported interventions to prevent adverse drug events among patients with cardiovascular disease. Value in Health 2022; 25: suppl 7 (s419-)

• Almukdad S, Kaddoura R, Arabi A.R, Almaraghi F, Al-Saadi Al Yafei S, Al-Badriyeh D. Cost-effectiveness of evolocumab versus standard therapy for the treatment of dyslipidemia in patients with cardiovascular disease in Qatar. Value in Health 2022; 25: suppl 7 (s389-)

• Abushanab D, Gulied A, Hamad A, Abdul Rouf P, Al Hail M, Elkassem W, El Hajj M, Al-Badriyeh D. Cost savings and cost avoidance with the inpatient clinical pharmacist interventions in a tertiary cancer. Value in Health 2022; 25: suppl 7 (s420-)

• Abushanab D, Liew D, Al-Badriyeh D, Marquina C, Ademi Z. Projections of future health and economic burden of cardiovascular disease among patients with type 2 diabetes mellitus in Australia. Estimates up to 2030. Value in Health 2022; 25: suppl 7 (s449-)

• Alhersh E, Rainkie D, Abushanab D, Al-Badriyeh D. A cost-effectiveness analysis for high versus low dose caffeine for the treatment of apnea in neonatal intensive care unit. Value in Health 2022; 25: suppl 7 (s338-)

• Abushanab D, Al-Badriyeh D, Marquina C, Bailey C, Jaam M, Liew D, Ademi Z. Cost-effectiveness of non-statin lipid-modifying agents for primary and secondary prevention of cardiovascular disease among patients with type 2 diabetes mellitus: a systematic review. Value in Health 2022; 25: suppl 1 (s98-)

• Al-Badriyeh D, Chbib S, Abdul Rouf P, Al Hail M, Elkassem W, Abushanab D. Cost-effectiveness analysis of dapagliflozin in addition to standard therapy in heart failure with reduced ejection fraction: a Qatari healthcare perspective. Journal of Emergency Medicine, Trauma and Acute Care 2022; 2022: suppl 1

• Abushanab D, Al-Badriyeh D, Marquina C, Bailey C, Jaam M, Liew D, Ademi Z. Cost-effectiveness of non-statin lipid-modifying agents for primary and secondary prevention of cardiovascular disease among patients with type 2 diabetes mellitus: a systematic review. Journal of Emergency Medicine, Trauma and Acute Care 2022; 2022: suppl 1

• Adel A, Abushanab D, Hamad A, Al-Badriyeh D, Yassin M. L-glutamine and crizanlizumab for adults with sickle cell disease (scd) in Qatar: a cost effectiveness analysis. Blood 2021; 138: suppl 1 (4945)

• Abushanab D, Abdul Rouf P, Al Hail M, Al Shaibi S, Al-Badriyeh D. Factors affecting the effectiveness of oral and intravenous ibuprofen in the management of preterm infants. A retrospective, cohort-based study. JACCP, Journal of the American College of Clinical Pharmacy 2021; 4: 9 (1234-1235)

• Al-Shaibi S, Abushanab D, Alhersh E, Kaddoura R, Abdul Rouf P, Al-Badriyeh D. The use of ibuprofen, including versus indomethacin or paracetamol/acetaminophen, for the closure of patent ductus arteriosus in preterm infants. A systematic review of meta-analyses. Value in Health 2021; 24: suppl 1 (s67-s68)

• Abushanab D, Mraiche F, Al-Badriyeh D. Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: a meta-analysis. Value in Health 2021; 24: suppl 1 (s22-)

• Abushanab D, Al-Badriyeh D. Efficacy and safety of ibuprofen plus paracetamol in a fixed-dose combination for acute postoperative pain in adults: meta-analysis and a trial sequential analysis. Value in Health 2021; 24: suppl 1 (s220-)

• Abushanab D, Abounahia F, Alsoukhni O, Abdelaal M, Al-Badriyeh D. Cost-effectiveness of midazolam on morphine therapy for pain relief in critically ill ventilated infants with respiratory distress syndrome. Value in Health 2021; 24: suppl 1 (s215-)

• Abushanab D, Al-Badriyeh D. Pharmacoeconomic evaluation of oral ibuprofen versus intravenous ibuprofen in preterm infants with patent ductus arteriosus in the neonatal intensive care units in Qatar. Value in Health regional issues 2020; 22: suppl (s44-)

• Abushanab D, Abdul Rouf P, Al Hail M, Al-Shaibi S, Viswanathan V, Kamal R, Parappil H, Elkassem W, Al-Badriyeh D. Clinical and economic evaluation of oral versus intravenous ibuprofen therapy in preterm infants with patent ductus arteriosus in the neonatal intensive care unit in Qatar. Value in Health regional issues 2020; 22: suppl (s45-)

• Abdelaal M, Valappil R, Alsokhni O, Babiker A, Al-Badriyeh D. A clinical and economic evaluation of surfactant therapy for meconium aspiration syndrome in the neonatal intensive care setting in Qatar. Value in Health 2020; 23: suppl 1 (s155-)

• Abdelaal M, Valappil R, Alsokhni O, Babiker A, Al-Badriyeh D. A clinical and economic analysis of the single-dose versus multiple-dose approaches of surfactant use in meconium aspiration syndrome in neonatal intensive care units in Qatar. Value in Health 2020; 23: suppl 1 (s155-)

• Almukdad S, Elewa H, Al-Badriyeh D. Cost-effectiveness of the cyp2c19 genotype-guided antiplatelet therapy compared to universal use of ticagrelor or clopidogrel in Qatar. Value in Health 2020; 23: suppl 1 (s96-s97)